10 February 2015
PSE's gCOAS heralds breakthrough in computational oral absorption analysis
Formulation scientists can "bring new and better drugs to market earlier"
LONDON, 10 February 2015 --- Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced its new gCOAS® product for computational oral absorption at the Drug Development and Formulation Summit in Düsseldorf.
gCOAS, co-developed within the Systems-based Pharmaceutics (SbP) Alliance, is an analysis tool for a priori prediction of drug absorption in the human intestine as a function of product formulation parameters and ingestion conditions.
It provides formulation scientists with a tool that allows them to easily and quickly screen the performance of new formulations. The ultimate objective is to design a good dosage form in terms of amount of active pharmaceutical ingredient (API), particle size distribution of the API crystals, and other relevant attributes.
gCOAS aims to give unprecedented confidence in the accuracy of predictions of fractions absorbed using basic compound data, allowing more comprehensive early stage screening of promising candidate molecules and enabling the design of better formulations throughout the development lifecycle. These improved formulations reduce the risk to healthy volunteers and patients, as well as help reduce the number of trials, making it possible to bring new and better drugs to market earlier.
gCOAS is a key component of PSE?s Systems-based Pharmaceutics vision, in which the formulation and manufacturing decisions are based on their effect on the efficacy of the drug. The ultimate goal of SbP is to identify the drug formulation that gives you the desired bioavailability while satisfying manufacturing constraints such as flowability and content uniformity as early as possible in the development cycle.
Contact: Kate Burness, +44-20-8563-0888, email@example.com
Click on a File to open it, then select "Save As" to download and save.